Abstract
Consistency of Response in the COMPASS Study [Breath Powered™ Nasal Delivery of 22 mg Sumatriptan Powder (AVP-825) Versus 100 mg Oral Sumatriptan in Acute Migraine: A Comparative Clinical Trial] (S23.001)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have